证券代码：688273 证券简称：麦澜德 公告编号：2025-007 南京麦澜德医疗科技股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2024 年，公司监事会严格按照《公司法》等法律法规以及《公司章程》和公 司《监事会议事规则》等制度的规定，认真地履行了自身的职责，依法独立行使 职权，促进公司规范运作，积极维护公司、全体股东及员工的合法权益。监事会 对公司的财务、股东大会决议等执行情况、董事会的重大决策程序及公司经营管 理活动的合法合规性、董事及高级管理人员履行其职务情况等方面进行了监督和 检查，促进公司的健康、持续发展。 表决结果：同意 3 票、反对 0 票、弃权 0 票。 本议案尚需提交 2024 年年度股东大会审议。 （二）审议通过《关于<公司 2024 年年度报告>及摘要的议案》 监事会认为：公司 2024 年年度报告的编制和审议程序符合相关法律法规及《公 司章程》等内部规章制度的规定；公司 2024 年年度报告的内容与格式符合相关规 定，公允地反映了公司 2024 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-006 南京麦澜德医疗科技股份有限公司 第二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京麦澜德医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 12 日以 邮件方式发出第二届董事会第十二次会议通知（以下简称"本次会议"），本次会议 于 2025 年 4 月 22 日以现场及通讯方式召开，由董事长杨瑞嘉先生召集并主持， 本次会议应到董事 8 人，实到董事 8 人。本次会议的召集召开符合《中华人民共 和国公司法》《上海证券交易所科创板股票上市规则》等相关法律法规、规范性 文件及《南京麦澜德医疗科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，作出的决议合法、有效。 二、董事会会议审议情况 经与会董事审议表决，形成会议决议如下： （一）审议通过《关于<公司 2024 年度董事会工作报告>的议案》 公司董事会严格按照有关法律法规、规范性文件以及公司制度规定，切实履 行股东赋予的董 ...

一、利润分配方案内容 证券代码：688273 证券简称：麦澜德 公告编号：2025-008 南京麦澜德医疗科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 每股分配比例：每股派发现金红利 0.40 元（含税），不进行公积金转增股 本，不送红股。 ● 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司回购专用 证券账户中的股份数为基数，具体日期将在权益分派实施公告中明确。 ● 如在实施权益分派的股权登记日前公司总股本扣除公司回购专用证券账户 中的股份数发生变动的，拟维持每股分配比例不变，相应调整分配总额，并将另 行公告具体调整情况。 ● 公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 经中兴华会计师事务所（特殊普通合伙）审计，南京麦澜德医疗科技股份有 限公司（以下简称"公司"）2024 年度归属于上市公司股东 ...

中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址(location):北京市丰台区丽泽路 20 号丽泽 SOHO B 座 20 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China (tel):010-51423818 传真(fax):010-51423816 审计报告 中兴华审字(2025)第 020779 号 南京麦澜德医疗科技股份有限公司全体股东: 一、审计意见 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于麦澜德公司,并履行了职业道德方面的 其他责任。我们相信,我们获取的审计证据是充分、适当的,为发表审计意见提供 了基础。 三、关键审计事项 关键审计事项是根据我们的职业判断,认为对本期财务报表审计最为重要的事 项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景,我们不对 这些事项单独发 ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南京 麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》等有关规定，对麦澜德 2024 年度募集资金存放与实际使用 情况进行了认真、审慎地核查，核查情况如下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限公司首次公开发行股票注册的批复》（证监许可〔2022〕1189 号），公司首次 向社会公开发行人民币普通股 2,500 万股，每股发行价格为人民币 40.29 元，募集 资金总额为 1,007,250,000.00 元；减除发行费用 97,491,500.00 元（不含税）后，募 集资金净 ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 使用暂时闲置自有资金购买理财产品的核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南京 麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》等有关规定，对麦澜德使用暂时闲置自有资金购买理 财产品的事项进行了认真、审慎的核查，核查情况如下： 一、使用闲置自有资金购买理财产品的概况 （一）投资目的 在不影响公司正常生产经营、充分保障公司开支需求并有效控制风险的前提 下，公司使用暂时闲置自有资金购买风险较低、安全性高、流动性好的理财产品， 有利于提高资金使用效益，增强公司短期现金的管理能力，获得更好的财务收益， 为公司及股东获取更多回报。 （二）投资品种 公司将按照相关规定严格控制风险，对投资产品进行严格评估，将自有资金 投向风险较低、安全性高、流动性好的理财产品，投资产品不得用于质押，不得 用于以证券投资为目的的投资行为。 （三）投资产品的额度 ...

中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS ILb 地址(location): 北京市丰台区丽泽路 20 号丽泽 S0H0 B 座 20 层 Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电话(tel):010-51423818 传真(fax):010-51423816 内部控制审计报告 中兴华内控审计字(2025)第 020033 号 南京麦澜德医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了南京麦澜德医疗科技股份有限公司(以下简称"麦澜德公司")2024年 12 月 31 日的财务报告内部控制的有效性。 一、麦澜德公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是麦澜德公司董 事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审 计意 ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2025 年度日常关联交易预计额度的核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南京麦澜德 医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票并在科创 板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等有关规定，对麦澜德 2025 年度日常关联交易预计额度的事项进行了认 真、审慎的核查，核查情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 22 日，公司召开了第二届董事会独立董事专门会议第四次会议， 事前审议了《关于 2025 年度日常关联交易额度预计的议案》。全体独立董事认为： 本次 2025 年度日常关联交易预计符合公司日常经营发展所需，属于正常的商业交 易行为，不存在预计非必要关联交易的情况。上述日常关联交易计划的定价依据 公允、合理，遵循市场公平交易原则，不存在损害公司及其股东尤其是中小股东 利益的情形。该等关联交易不会对公司的独立性产生不利影响 ...

Financial Performance - The company achieved a net profit attributable to shareholders of 101,581,195.08 CNY for the fiscal year 2024[7]. - The proposed cash dividend is 4.00 CNY per 10 shares, totaling 39,123,142.80 CNY to be distributed among 97,807,857 shares[7]. - As of December 31, 2024, the company's distributable profits amounted to 158,884,120.13 CNY[7]. - The total share capital of the company is 100,000,000 shares, with 2,192,143 shares in the repurchase account excluded from dividends[7]. - The company does not plan to increase capital through reserves or issue bonus shares[7]. - The company's operating revenue for 2024 reached ¥424,549,436.34, representing a 24.57% increase compared to ¥340,824,682.52 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥101,581,195.08, up 13.10% from ¥89,817,910.06 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥82,002,994.57, reflecting a 14.63% increase from ¥71,537,863.76 in 2023[23]. - The company's total assets as of the end of 2024 were ¥1,546,621,500.61, a 0.83% increase from ¥1,533,923,915.26 at the end of 2023[23]. - Basic earnings per share for 2024 were ¥1.0309, which is a 14.77% increase compared to ¥0.8982 in 2023[24]. - The net cash flow from operating activities for 2024 was ¥122,508,138.42, a decrease of 10.52% from ¥136,908,370.75 in 2023[23]. - The company reported a quarterly revenue of ¥104,336,800.77 in Q1 2024, with net profit attributable to shareholders of ¥36,286,016.09[26]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, aiming for a 10% market share by the end of 2025[13]. - A strategic acquisition of a competitor is in progress, which is expected to enhance the company's product portfolio and increase market competitiveness[13]. - The company is actively involved in key national and provincial research projects, including AI-assisted pelvic floor rehabilitation technology[34]. - The company is expanding its international market presence by developing an international version of the PI-ONE system[37]. - The company is focusing on integrating AI technology into its diagnostic processes, aiming to enhance decision-making efficiency and accuracy in treatment plans[44]. - The company is committed to enhancing its product matrix by leveraging optical imaging, focused ultrasound, and AI technologies to improve diagnostic capabilities[40]. - The company aims to enhance women's health and beauty sectors, focusing on reproductive rehabilitation and anti-aging technologies[65]. - The company is focusing on expanding its product offerings in pelvic floor rehabilitation equipment and services[166]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential deals[199]. Research and Development - The company is investing RMB 50 million in R&D for innovative technologies in medical devices[13]. - The R&D investment as a percentage of operating revenue decreased to 14.67% in 2024 from 17.09% in 2023, a reduction of 2.42 percentage points[24]. - The company has established an independent R&D center with various specialized departments to continuously optimize product performance through technological upgrades[53]. - The company has developed a pelvic floor rehabilitation electrophysiology technology platform, enabling personalized treatment for various pelvic floor disorders[71]. - The company has developed the world's first intelligent pelvic floor diagnosis and treatment system, PI-ONE, which utilizes AI algorithms for intelligent analysis of assessment data[185]. - The company is focusing on personalized treatment plans through AI and big data analysis to maintain industry competitiveness[93]. - The company has developed a unique multimodal motion closed-loop control system that provides individualized treatment plans based on real-time recovery status, enhancing rehabilitation outcomes[109]. - The company has initiated significant research projects, including a key technology development project for a medical ultrasound multimodal foundational model, expected to run from 2024 to 2027[85]. Product Development and Innovation - New product development includes a cutting-edge medical device expected to launch in Q3 2024, projected to generate RMB 200 million in sales[13]. - The company launched the PI-ONE system, an AI-assisted solution for pelvic floor rehabilitation, enhancing assessment and treatment capabilities[35]. - The company is developing next-generation vaginal electrodes tailored to women's anatomy, enhancing treatment effectiveness[72]. - The company has developed a new generation of pelvic floor ultrasound intelligent diagnostic systems, with a total expected investment of ¥40,520,000[90]. - The company has developed a multi-channel high-frequency ultrasound technology platform, capable of producing up to 16 channels of focused ultrasound output, significantly enhancing clinical application options[76]. - The company has introduced a uterine restoration device in the field of obstetrics and gynecology, featuring automated control with three motion trajectories and nine speed adjustment levels, improving clinical efficiency[76]. - The company is developing next-generation laser products, including picosecond dual-wavelength laser devices, to enhance its optical and laser product line[81]. - The company has launched the 3D Skin Analyzer P2 (Professional Version) and AI Morphology Analyzer, enhancing user experience by reducing AI analysis time[96]. Governance and Compliance - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[3]. - The company has established a system for independent directors to enhance decision-making fairness and scientificity[192]. - The company’s governance structure is compliant with the regulations set by the China Securities Regulatory Commission, ensuring operational independence[193]. - The company held 5 shareholder meetings, 8 board meetings, and 7 supervisory meetings during the reporting period, ensuring robust governance practices[192]. - The independent directors and supervisors have maintained their shareholdings at 8 shares each throughout the reporting period[197]. Market Trends and Industry Insights - The overall revenue of China's medical device industry reached CNY 1.31 trillion in 2023, with an average annual growth rate of 10% from 2014 to 2023, indicating a robust market[56]. - The rehabilitation medical device market in China is projected to reach CNY 94.15 billion by 2026, driven by an aging population and increasing chronic disease prevalence[58]. - The prevalence of pelvic floor dysfunction (PFD) among women in China is increasing, with a reported incidence rate of 65.24% among women aged 53.61 years in Beijing in 2018[60]. - The infertility rate in China is projected to rise from 12.5%-15% in 2016 to 18% by 2025, translating to approximately 60 million patients[61]. - The annual number of abortions in China reached 9.76 million in 2019, indicating a significant impact on women's reproductive health and fertility[61]. - The market for light medical aesthetics in China is projected to reach approximately 415.7 billion RMB by 2030, indicating significant growth potential[61]. - The clinical demand for reproductive rehabilitation is rapidly increasing, with infertility rates rising from 11.9% in 2007-2010 to nearly 18% in 2020, affecting approximately 50.5 million couples in China[174]. Operational Efficiency and Cost Management - The company is actively monitoring raw material price fluctuations to optimize procurement strategies and maintain cost efficiency[121]. - The company achieved operating revenue of CNY 424.55 million in 2024, a 24.57% increase from CNY 340.82 million in the same period last year[125]. - The main business revenue increased by 30.40% to CNY 418.41 million, with main business costs rising by 42.76% to CNY 116.13 million, resulting in a decrease in gross margin by 2.40 percentage points[127]. - Operating expenses have been reduced by 5% due to efficiency improvements in the supply chain[199]. - The intelligent cost control management platform will integrate budget control and risk warning functions to achieve refined cost management[190].

Financial Performance - The company's operating revenue for Q1 2025 was ¥118,279,190.58, representing a 13.36% increase compared to ¥104,336,800.77 in the same period last year[4] - Net profit attributable to shareholders was ¥39,859,710.56, up 9.85% from ¥36,286,016.09 year-over-year[4] - The net profit after deducting non-recurring gains and losses was ¥37,582,005.84, reflecting an 11.60% increase from ¥33,674,390.42 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥118,279,190.58, an increase of 13.5% compared to ¥104,336,800.77 in Q1 2024[18] - Operating costs for Q1 2025 were ¥79,132,614.70, up from ¥67,441,073.51 in Q1 2024, reflecting a 17.4% increase[19] - Net profit for Q1 2025 was ¥39,283,674.65, compared to ¥38,187,419.68 in Q1 2024, representing a growth of 2.9%[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.4073, an increase from ¥0.3660 in Q1 2024[20] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥662,603.27, a significant decrease of 116.33% compared to a net inflow of ¥4,058,727.37 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was ¥102,616,856.12, compared to ¥89,637,302.03 in Q1 2024, indicating a growth of 14.9%[21] - Net cash flow from operating activities decreased to -$662,603.27 from $4,058,727.37 year-over-year[22] - The company reported a total cash inflow from operating activities of $107,767,124.57, compared to $96,522,539.04 previously[22] - Total cash outflow from operating activities increased to $108,429,727.84 from $92,463,811.67[22] Research and Development - Research and development expenses totaled ¥15,004,116.64, which is a 15.87% increase from ¥12,949,133.49 in the previous year[4] - The proportion of R&D expenses to operating revenue increased to 12.69%, up 0.28 percentage points from 12.41% year-over-year[5] - Research and development expenses for Q1 2025 were ¥14,479,582.13, up from ¥12,949,133.49 in Q1 2024, reflecting an increase of 11.8%[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,524,160,130.51, a decrease of 1.45% from ¥1,546,621,500.61 at the end of the previous year[5] - Total liabilities decreased to ¥139,219,395.83 from ¥199,662,048.19, showing a reduction of 30.3%[16] - Total current assets decreased to RMB 953,390,381.27 from RMB 1,001,656,821.36, indicating a decline of approximately 4.8%[14] - The company's accounts receivable increased to RMB 23,805,181.67 from RMB 15,179,617.47, representing a growth of about 56.8%[14] - The inventory decreased to RMB 67,359,597.90 from RMB 73,049,282.47, reflecting a decline of approximately 7.3%[14] - The company's long-term equity investments were valued at RMB 19,725,632.10, a slight decrease from RMB 20,472,265.48[14] - The total non-current assets remained relatively stable, with a slight increase in construction in progress to RMB 229,194,763.36 from RMB 203,001,882.28[14] - The company's goodwill remained unchanged at RMB 41,899,723.22, indicating stability in this asset category[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,927[8] - The top two shareholders, Yang Ruijia and Shi Zhihuai, held 19.36% and 18.15% of the shares, respectively[9] - The repurchase account held 2,190,943 shares, representing 2.19% of total shares as of March 31, 2025[12] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[11] - There were no significant changes in the participation of major shareholders in margin trading or securities lending activities[11]